BFM
QNCX icon

Boothbay Fund Management’s Quince Therapeutics QNCX Stock Holding History

Boothbay Fund Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-71
Closed -$1.29M – 2154
2021
Q3 		$1.29M Buy
+71
New +$1.13M 0.04% 635

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boothbay Fund Management's QNCX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 13,911 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #1818 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in QNCX as recently as Q3 2020.

Boothbay Fund Management first reported a position in QNCX in Q3 2020 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Boothbay Fund Management held 13,911 shares of Quince Therapeutics worth $253K as of Q2 2026.
  • Quince Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Quince Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1818 holding.
  • Boothbay Fund Management first reported a position in Quince Therapeutics in Q3 2020 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.